Questions a plan sponsor actually asks.
What is Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide used for?
Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide blocks HIV replication by inhibiting reverse transcriptase.
Is there a generic for Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide?
No. Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide is brand-only with no generic equivalents currently in market.
How much does my plan pay for Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide?
Across 329 Part D plans, Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide averages $136.74/unit (NADAC). Lowest available: $136.73/unit. Highest in distribution: $136.74/unit.
Is Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide on the FDA shortage list?
No. Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide is not currently on the FDA Drug Shortage Database.
5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (4 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.